Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > BioAlliance Pharma Receives Market Approval for Loramyc® in the United Kingdom and Denmark

Abstract:
BioAlliance Pharma SA (Paris: BIO) today announces, following the end of the European Mutual Recognition Procedure last December (with France as Reference Member State) that it has just received the Marketing Authorisation for Loramyc® in the UK and Denmark.

BioAlliance Pharma Receives Market Approval for Loramyc® in the United Kingdom and Denmark

PARIS, France | Posted on January 9th, 2008

The grant of the Marketing Authorisation in the UK represents an important milestone for BioAlliance Pharma especially with the payment of €2.5 million by its partner SpePharm, according to the terms of the agreement signed in March 2007, which led to the creation of the SpeBio JV for the distribution of Loramyc® in Europe.

"We are delighted of this European success which confirms the quality and the efficiency of our development and regulatory teams and experts. Currently being launched in France, Loramyc® will be present on the European market in 2008 as planned. The other main European countries should grant their Marketing Authorisation for Loramyc® in the very near future", stated Dominique Costantini Chief Executive Officer.

####

About BioAlliance Pharma SA
BioAlliance Pharma SA is a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV. The company develops and commercializes innovative products which address resistance issues. The company has launched its first portfolio product (Loramyc®) in France and the compound is currently in Phase III clinical development in oropharyngeal candidiasis in the USA. In addition, two other innovative products are currently in Phase III clinical trials: acyclovir Lauriad® in oral herpes (based on the same Lauriad® muco-adhesive technology as Loramyc®, which enables targeted release at the disease site) and doxorubicin Transdrug® in primary liver cancer (based on the Transdrug® nanoparticle technology, designed specifically for intracellular targeting of resistant cells). The company is also developing a new therapeutic entities program focused on the oncology and HIV markets.

In 2007, the company has established strategic alliances for commercializing Loramyc® in Europe (with JV SpeBio) and the USA (with Par Pharmaceutical).

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the reference document approved by the AMF on April 6th 2007 under the number R. 07-031, which is available on the AMF website ( http://www.amf-france.org ) or on BioAlliance Pharma S.A.'s website ( http://www.bioalliancepharma.com ).

For press releases and other company information, visit www.bioalliancepharma.com.

For more information, please click here

Contacts:
BioAlliance Pharma SA
Dominique Costantini
+33 1 45 58 76 01
President and CEO

or
ALIZE RP
Caroline Carmagnol
+33 6 64 18 99 59

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Toyocolor to Launch New Carbon Nanotube Materials at nano tech 2015 January 24th, 2015

NANOPOSTER 2015 - 5th Virtual Nanotechnology Conference - call for abstracts January 24th, 2015

Nanosensor Used for Simultaneous Determination of Effective Tea Components January 24th, 2015

The latest fashion: Graphene edges can be tailor-made: Rice University theory shows it should be possible to tune material's properties January 24th, 2015

Govt.-Legislation/Regulation/Funding/Policy

The latest fashion: Graphene edges can be tailor-made: Rice University theory shows it should be possible to tune material's properties January 24th, 2015

Scientists 'bend' elastic waves with new metamaterials that could have commercial applications: Materials could benefit imaging and military enhancements such as elastic cloaking January 23rd, 2015

Harper Government Supports Research Innovation in Western Canada January 22nd, 2015

EnvisioNano: An image contest hosted by the National Nanotechnology Initiative (NNI) January 22nd, 2015

Nanomedicine

Teijin to Participate in Nano Tech 2015 January 22nd, 2015

2nd International Conference on Infectious Diseases & Nanomedicine (December 15-18, 2015, Kathmandu, NEPAL) January 22nd, 2015

Anti-microbial coatings with a long-term effect for surfaces – presentation at nano tech 2015 in Japan January 21st, 2015

A spoonful of sugar in silver nanoparticles to regulate their toxicity January 21st, 2015

Announcements

Toyocolor to Launch New Carbon Nanotube Materials at nano tech 2015 January 24th, 2015

NANOPOSTER 2015 - 5th Virtual Nanotechnology Conference - call for abstracts January 24th, 2015

Nanosensor Used for Simultaneous Determination of Effective Tea Components January 24th, 2015

The latest fashion: Graphene edges can be tailor-made: Rice University theory shows it should be possible to tune material's properties January 24th, 2015

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE